On 26 thMay 2017, KTE-C19(axicabtagene ciloleucel) was granted Priority Review by the U.S. Food and Drug Administration ( FDA) for the treatment of patients who are ineligible for transplant with R/R NHL.
Results of the phase II ZUMA-1 trial ( NCT02348216) form the basis of this Priority Review. Preliminary data from the ZUMA-1 trial were presented in April during AACR 2017, which the Lymphoma Hub reported on.
As a result of this Priority Review, a decision on Kite Pharma’sBiologics License Application (BLA; submitted in March 2017) for KTE-C19 will be reached 4 months earlier than if under standard review.
Kite Pharma also plan to file for potential approval for KTE-C19 in Europe for R/R DLBCL patients; this application is expected to take place in Q3 of this year.